Clinical Trial Update: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update announcing a Phase 1/2 study of epcoritamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma (various subtypes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Large B-cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Genmab | Conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING